UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 199

Sortiert nach

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Cancer cell, 2022-03, Vol.40 (3), p.289-300.e4

2022

Volltextzugriff (PDF)

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma

Journal of thoracic oncology, 2018-01, Vol.13 (1), p.124-133

2018

Volltextzugriff (PDF)

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab

Scientific reports, 2021-07, Vol.11 (1), p.13912-13912, Article 13912

2021

Volltextzugriff (PDF)

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients

PloS one, 2021-02, Vol.16 (2), p.e0246486-e0246486

2021

Volltextzugriff (PDF)

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

Nature medicine, 2023-04, Vol.29 (4), p.859-868

2023

Volltextzugriff (PDF)

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

Journal of clinical oncology, 2024-01, Vol.42 (3), p.324

2024

Volltextzugriff (PDF)

Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade

Cancer cell, 2024-03, Vol.42 (3), p.429-443.e4

2024

Volltextzugriff (PDF)

Automated tumor immunophenotyping predicts clinical benefit from anti‐PD‐L1 immunotherapy

The Journal of pathology, 2024-06, Vol.263 (2), p.190-202

2024

Volltextzugriff (PDF)

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Nature (London), 2024-03, Vol.627 (8004), p.646-655

2024

Volltextzugriff (PDF)

Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150

Tumor biology, 2024-03, Vol.46 (s1), p.S177-S190

2024

Volltextzugriff (PDF)

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy

JCO precision oncology, 2021-11, Vol.5, p.827

2021

Volltextzugriff (PDF)

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade

Journal for immunotherapy of cancer, 2021-04, Vol.9 (4), p.e002231

2021

Volltextzugriff (PDF)

Relationship between kinetic stability and immunogenicity of HLA‐DR4/peptide complexes

European journal of immunology, 2002-03, Vol.32 (3), p.662-670

2002

Volltextzugriff (PDF)

579-B TIGIT and PD-L1 co-blockade promotes clonal expansion of non-exhausted anti-tumour CD8+ T cells by facilitating costimulation

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 2), p.A1803-A1803

2023

Volltextzugriff (PDF)

Abstract 5518: Tumor infiltrating B cells and tertiary lymphoid structures are associated with tumor response to PD-L1 blockade in NSCLC

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5518-5518

Patil, Namrata S.

2020

Volltextzugriff (PDF)

Secure Steganography Approach using 2 X-Box Mapping Technique

International journal of advanced research in electrical, electronics and instrumentation engineering, 2015-03, Vol.4 (3), p.1507-1513

Alaknanda S. Patil, Namrata S. Malge

2015

Volltextzugriff (PDF)

DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms

Immunology, 2010-09, Vol.131 (1), p.18-32

2010

Volltextzugriff (PDF)

Fluorescent derivatization of a protease antigen to track antigen uptake and processing in human cell lines

BMC immunology, 2004-06, Vol.5 (1), p.12-12

2004

Volltextzugriff (PDF)

Accessory molecules for MHC class II peptide loading

Current opinion in immunology, 2000-02, Vol.12 (1), p.99-106

2000

Volltextzugriff (PDF)

Rheumatoid Arthritis (RA)-Associated HLA-DR Alleles Form Less Stable Complexes with Class II-Associated Invariant Chain Peptide Than Non-RA-Associated HLA-DR Alleles

The Journal of immunology (1950), 2001-12, Vol.167 (12), p.7157-7168

2001

Volltextzugriff (PDF)

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab

PloS one, 2021-02, Vol.16 (2), p.e0246486

2021

Volltextzugriff (PDF)

1 – 25 von 199

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(152)
Mit Volltextzugriff
(173)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(198)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(102)
Life Sciences & Biomedicine
(80)
Humans
(51)
Oncology
(23)
Female
(22)
Male
(16)
Patients
(15)
Dentistry, Oral Surgery & Medicine
(13)
Middle Aged
(13)
Technology
(12)
Aged
(11)
Animals
(11)
Adult
(10)
Original
(10)
Science & Technology - Other Topics
(10)
General & Internal Medicine
(9)
Immunotherapy
(9)
Lung Neoplasms - Drug Therapy
(9)
Physical Sciences
(9)
Dentistry
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma

Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab (anti-PD-L1) treated non-small cell lung cancer patients

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade

Automated tumor immunophenotyping predicts clinical benefit from anti‐PD‐L1 immunotherapy

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial

Relationship between kinetic stability and immunogenicity of HLA‐DR4/peptide complexes

579-B TIGIT and PD-L1 co-blockade promotes clonal expansion of non-exhausted anti-tumour CD8+ T cells by facilitating costimulation

Abstract 5518: Tumor infiltrating B cells and tertiary lymphoid structures are associated with tumor response to PD-L1 blockade in NSCLC

Secure Steganography Approach using 2 X-Box Mapping Technique

DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms

Fluorescent derivatization of a protease antigen to track antigen uptake and processing in human cell lines

Accessory molecules for MHC class II peptide loading

Rheumatoid Arthritis (RA)-Associated HLA-DR Alleles Form Less Stable Complexes with Class II-Associated Invariant Chain Peptide Than Non-RA-Associated HLA-DR Alleles

C-reactive protein reduction post treatment is associated with improved survival in atezolizumab

Suchergebnisse filtern